OA10341A - Anti-hiv triple combination - Google Patents

Anti-hiv triple combination Download PDF

Info

Publication number
OA10341A
OA10341A OA60946A OA60946A OA10341A OA 10341 A OA10341 A OA 10341A OA 60946 A OA60946 A OA 60946A OA 60946 A OA60946 A OA 60946A OA 10341 A OA10341 A OA 10341A
Authority
OA
OAPI
Prior art keywords
zidovudine
combination
loviride
htv
ciaims
Prior art date
Application number
OA60946A
Other languages
English (en)
Inventor
Paulus Aloysius Maria Stoffels
Koenraad Jozef Lodewij Andries
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of OA10341A publication Critical patent/OA10341A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
OA60946A 1994-07-01 1996-12-31 Anti-hiv triple combination OA10341A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP94201897 1994-07-01

Publications (1)

Publication Number Publication Date
OA10341A true OA10341A (en) 1997-10-07

Family

ID=8217000

Family Applications (1)

Application Number Title Priority Date Filing Date
OA60946A OA10341A (en) 1994-07-01 1996-12-31 Anti-hiv triple combination

Country Status (25)

Country Link
EP (1) EP0768881B1 (et)
JP (1) JP2945481B2 (et)
KR (1) KR100218495B1 (et)
CN (1) CN1091599C (et)
AP (1) AP9600896A0 (et)
AT (1) ATE218867T1 (et)
AU (1) AU693911B2 (et)
BG (1) BG101175A (et)
BR (1) BR9508201A (et)
CA (1) CA2193489A1 (et)
CZ (1) CZ375596A3 (et)
DE (1) DE69527066T2 (et)
EE (1) EE9600180A (et)
FI (1) FI965292A0 (et)
HU (1) HUT77720A (et)
IL (1) IL114415A0 (et)
MX (1) MX9700044A (et)
MY (1) MY130597A (et)
NO (1) NO965556L (et)
OA (1) OA10341A (et)
PL (1) PL317891A1 (et)
SK (1) SK168196A3 (et)
TW (1) TW401303B (et)
WO (1) WO1996001110A2 (et)
ZA (1) ZA955471B (et)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998008539A1 (en) * 1996-08-26 1998-03-05 Chiron Corporation Postinfection human immunodeficiency virus (hiv) vaccination therapy
EP0872233A1 (en) * 1997-04-14 1998-10-21 Janssen Pharmaceutica N.V. Antiretroviral compositions with improved bioavailability
JP4919566B2 (ja) 1999-09-24 2012-04-18 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 抗ウイルス組成物
MY169670A (en) * 2003-09-03 2019-05-08 Tibotec Pharm Ltd Combinations of a pyrimidine containing nnrti with rt inhibitors
US9044509B2 (en) 2006-02-03 2015-06-02 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Inhibition of HIV infection through chemoprophylaxis
AR065720A1 (es) 2007-03-14 2009-06-24 Tibotec Pharm Ltd Polvos para reconstitucion que comprenden rilpivirina dispersos en ciertos polimeros. uso. proceso.
EP2435052B1 (en) 2009-05-27 2015-07-15 Hetero Research Foundation Solid oral dosage forms of lamivudine with isomalt
WO2018119371A1 (en) * 2016-12-23 2018-06-28 Temple University - Of The Commonwealth System Of Higher Education Anti-flaviviridae activity of anti-retroviral non-nucleoside (nnrtis) and nucleoside reverse transcriptase inhibitors (nnrtis)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0513917T4 (da) * 1991-05-16 2001-06-25 Glaxo Group Ltd Antivirale kombinationer indeholdende nukleosidanaloger

Also Published As

Publication number Publication date
ZA955471B (en) 1996-12-30
BG101175A (en) 1997-08-29
KR100218495B1 (en) 1999-09-01
EP0768881A2 (en) 1997-04-23
TW401303B (en) 2000-08-11
AU693911B2 (en) 1998-07-09
HUT77720A (hu) 1998-07-28
FI965292A (fi) 1996-12-31
MY130597A (en) 2007-07-31
EP0768881B1 (en) 2002-06-12
JP2945481B2 (ja) 1999-09-06
JPH09507858A (ja) 1997-08-12
SK168196A3 (en) 1997-05-07
EE9600180A (et) 1997-06-16
IL114415A0 (en) 1995-10-31
ATE218867T1 (de) 2002-06-15
AP9600896A0 (en) 1997-01-31
CN1091599C (zh) 2002-10-02
NO965556D0 (no) 1996-12-23
CN1151697A (zh) 1997-06-11
AU2924895A (en) 1996-01-25
DE69527066D1 (de) 2002-07-18
WO1996001110A3 (en) 1996-02-22
CA2193489A1 (en) 1996-01-18
WO1996001110A2 (en) 1996-01-18
MX9700044A (es) 1997-04-30
CZ375596A3 (en) 1997-04-16
PL317891A1 (en) 1997-04-28
HU9603627D0 (en) 1997-02-28
BR9508201A (pt) 1997-11-11
FI965292A0 (fi) 1996-12-31
DE69527066T2 (de) 2003-02-13
NO965556L (no) 1996-12-23

Similar Documents

Publication Publication Date Title
EP0876387B1 (en) Use of roxithromycin for the preparation of a medicament for improving the biological and antiviral activity of protease inhibitors
Cameron et al. Ritonavir and saquinavir combination therapy for the treatment of HIV infection
Mohri et al. Quantitation of zidovudine-resistant human immunodeficiency virus type 1 in the blood of treated and untreated patients.
Jacobson et al. Effect of foscarnet therapy on infection with human immunodeficiency virus in patients with AIDS
Groopman Current advances in the diagnosis and treatment of AIDS: an introduction
US7919101B2 (en) Highly potent synergistic combinations of human immunodeficiency virus (HIV) fusion inhibitors
OA10341A (en) Anti-hiv triple combination
CN117298114A (zh) 用于治疗hib感染和aids的方案
JPH03505579A (ja) ヒト免疫不全ウイルス（ｈｉｖ）のインビボにおける活性の阻害方法
Pollard Use of proteinase inhibitors in clinical practice
JPH02501220A (ja) 芳香族多環式ジオンを含有する抗ウイルス性薬剤及びレトロウイルス感染治療方法
US20050059745A1 (en) Antiviral therapy
Acosta et al. Agents for treating human immunodeficiency virus infection
Humphrey et al. A phase I trial of the pharmacokinetics, toxicity, and activity of KNI-272, an inhibitor of HIV-1 protease, in patients with AIDS or symptomatic HIV infection
Blanche et al. Randomized study of two doses of didanosine in children infected with human immunodeficiency virus
Hitchcock In vitro antiviral activity of didanosine compared with that of other dideoxynucleoside analogs against laboratory strains and clinical isolates of human immunodeficiency virus
Friedland et al. Stavudine (d4T, Zerit®)
Robertson‐Dallas et al. New drug interactions with zidovudine
Kahn The clinical use of didanosine
JPH02504283A (ja) 芳香族多環式ジオン化合物とヌクレオシド類似化合物とを含む抗ウイルス性組成物及びレトロウイルス感染を治療するための方法
Fletcher Current perspectives on antiretroviral therapy
WO1989002741A1 (en) Inhibitors of hiv-reverse transcriptase to treat aids
WO1989009055A1 (en) Antiviral composition containing aromatic polycyclic diones and nucleoside analogs and method for treating retrovirus infections
AU1133899A (en) Mixtures of dideoxy-nucleosides and hydroxycarbamide for inhibiting retroviral spread
Fletcher et al. Advances in pharmacotherapy: treatment of HIV infection